These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11830482)

  • 1. Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides.
    Decker T; Hipp S; Kreitman RJ; Pastan I; Peschel C; Licht T
    Blood; 2002 Feb; 99(4):1320-6. PubMed ID: 11830482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype.
    Decker T; Schneller F; Kronschnabl M; Dechow T; Lipford GB; Wagner H; Peschel C
    Exp Hematol; 2000 May; 28(5):558-68. PubMed ID: 10812246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells.
    Decker T; Schneller F; Sparwasser T; Tretter T; Lipford GB; Wagner H; Peschel C
    Blood; 2000 Feb; 95(3):999-1006. PubMed ID: 10648415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells.
    Liang X; Moseman EA; Farrar MA; Bachanova V; Weisdorf DJ; Blazar BR; Chen W
    Blood; 2010 Jun; 115(24):5041-52. PubMed ID: 20339095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells.
    Jahrsdörfer B; Wooldridge JE; Blackwell SE; Taylor CM; Griffith TS; Link BK; Weiner GJ
    J Leukoc Biol; 2005 Mar; 77(3):378-87. PubMed ID: 15582984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
    Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
    Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2).
    Robbins DH; Margulies I; Stetler-Stevenson M; Kreitman RJ
    Clin Cancer Res; 2000 Feb; 6(2):693-700. PubMed ID: 10690555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.
    Kreitman RJ; Wilson WH; White JD; Stetler-Stevenson M; Jaffe ES; Giardina S; Waldmann TA; Pastan I
    J Clin Oncol; 2000 Apr; 18(8):1622-36. PubMed ID: 10764422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells.
    Secchiero P; Melloni E; Tiribelli M; Gonelli A; Zauli G
    J Leukoc Biol; 2008 Feb; 83(2):434-7. PubMed ID: 17998303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of gene transfer with recombinant adeno-associated virus (rAAV) vectors into primary B-cell chronic lymphocytic leukemia cells by CpG-oligodeoxynucleotides.
    Theiss HD; Kofler DM; Büning H; Aldenhoff AL; Kaess B; Decker T; Baumert J; Hallek M; Wendtner CM
    Exp Hematol; 2003 Dec; 31(12):1223-9. PubMed ID: 14662328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.
    Singh R; Zhang Y; Pastan I; Kreitman RJ
    Clin Cancer Res; 2012 Jan; 18(1):152-60. PubMed ID: 22068660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of immunostimulatory CpG-oligonucleotides in chronic lymphocytic leukemia B cells.
    Decker T; Peschel C
    Leuk Lymphoma; 2001 Jul; 42(3):301-7. PubMed ID: 11699394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN.
    Jahrsdörfer B; Jox R; Mühlenhoff L; Tschoep K; Krug A; Rothenfusser S; Meinhardt G; Emmerich B; Endres S; Hartmann G
    J Leukoc Biol; 2002 Jul; 72(1):83-92. PubMed ID: 12101266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CpG oligodeoxynucleotide CpG-685 upregulates functional interleukin-21 receptor on chronic lymphocytic leukemia B cells through an NF-κB mediated pathway.
    Browning RL; Mo X; Muthusamy N; Byrd JC
    Oncotarget; 2015 Jun; 6(18):15931-9. PubMed ID: 26158860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins.
    Decker T; Oelsner M; Kreitman RJ; Salvatore G; Wang QC; Pastan I; Peschel C; Licht T
    Blood; 2004 Apr; 103(7):2718-26. PubMed ID: 14525789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-CLL cells acquire APC- and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21.
    Hagn M; Blackwell SE; Beyer T; Ebel V; Fabricius D; Lindner S; Stilgenbauer S; Simmet T; Tam C; Neeson P; Trapani JA; Schrezenmeier H; Weiner GJ; Jahrsdörfer B
    Int Immunol; 2014 Jul; 26(7):383-95. PubMed ID: 24497611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia.
    Kreitman RJ; Chaudhary VK; Kozak RW; FitzGerald DJ; Waldman TA; Pastan I
    Blood; 1992 Nov; 80(9):2344-52. PubMed ID: 1421405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Application of CpG Oligodeoxynucleotide Immunostimulation in Chromosome Study of Chronic Lymphoblastic Leukemia].
    Mai DI Na AEK; Liu H; Wang YL; Wang YC; Huang Q; Wang ZS; Gu ZLNE; Lang T; Nie YL; An L; A ZGL; Mu HTBE; Zhang XY; Fu L; Ai HMJ; Mao M; Wang XM; Li Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):470-475. PubMed ID: 32319381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity.
    Kreitman RJ; Stetler-Stevenson M; Jaffe ES; Conlon KC; Steinberg SM; Wilson W; Waldmann TA; Pastan I
    Clin Cancer Res; 2016 Jan; 22(2):310-8. PubMed ID: 26350263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Responses in refractory hairy cell leukemia to a recombinant immunotoxin.
    Kreitman RJ; Wilson WH; Robbins D; Margulies I; Stetler-Stevenson M; Waldmann TA; Pastan I
    Blood; 1999 Nov; 94(10):3340-8. PubMed ID: 10552943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.